Margaret Kaczor's Stock Ratings

William Blair Analyst

Margaret Kaczor is an analyst at William Blair. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/24/2024

Overall Average Return

-13.4%

Smart Score

Overall Average Return Percentile

16th

Number of Ratings

38

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs

Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries.

Glaucoma Player Sight Sciences Stock Falls More Than 30%: Analyst Warns Of Lingering Concerns Over Coverage

Sight Sciences Inc (NASDAQ: SGHT) shares are trading lower after the company issued third-quarter total revenue guidance below estimates and cut full-year 2023 revenue

MedTech Stock Cooper Companies Poised For Organic Growth, Analysts Have Confidence In Stock

Wednesday, Cooper Companies (NYSE: COO) reported Q3 adjusted EPS of $3.35, slightly ahead of the consensus Of $3.34.</

Strong Zio AT Business Growth Propels iRhythm's Q2 Revenue Surge, Analysts Say Warning Letter Manageable

iRhythm Technologies Inc's (NASDAQ: IRTC) revenue of $124.1 million increased 21.6% Y/Y, beating the consensus of $120.3

ResMed's Q4 Results: Analysts Say Uncertain Market Dynamics Follow Amid Philips Re-Entry

ResMed Inc (NYSE: RMD) posted Q4 adjusted EPS of $1.60, up from $1.49 a year ago, missing the consensus of $1.67.

STAAR Surgical Stock Tumbles After Q2 Earnings: Here's Why

STAAR Surgical Company's (NASDAQ: STAA) Q2 sales reached $92.3 million, up 14% Y/Y, driven by ICL sales growth of 19% and ICL unit growth of 21%, missing the

Barclays Loses Confidence In Newell Brands

Six Reasons Why William Blair Turned Bullish On Abbot Laboratories

Time To Buy EndoChoice, William Blair Says

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook